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INTRODUCTION (Table 1)
This short version complies with the intention ex-
pressed in the methodological introduction to the
full text Italian Guidelines for the use of antiretro-
viral drugs and the diagnostic-clinical management
of people with HIV-1 infection. By definition, this
version should not be considered completely ex-
haustive with respect to the full text version of
the Guidelines available at the website:
http://www.salute.gov.it/imgs/C_17_pubblicazio-
ni_1301_allegato.pdf.
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The aim of this version is simply to render certain
concepts expressed in the document more usable,
by specific circulation in booklet form, inviting
the reader to refer to the extended version for fur-
ther information and full details.
As in the previously released version, it was de-
cided not to discuss in toto certain fundamental
parts of the extended versions such as the popu-
lations requiring special attention (elderly,
women, immigrants, children), the conditions re-
quiring special attention (drug and/or alcohol ad-
diction, detention) or the situations requiring spe-
cial attention (transplants). 
For all these populations, conditions or situations,
reference should be made to the full text version
of the Guidelines.
Lastly, it was decided to refer the reader to the
extended version for all bibliographic citations,
except for the essential references cited at the end
of this version.
PATIENT ASSESSMENT 
AND PREPARATION
The initiation of combination antiretroviral ther-
apy (cART) should be considered a crucial mo-
ment in the management of HIV infection which
requires:
- particular competence of the attending physi-
cian;
- comprehension and agreement on the part of
the patient.
Physician-patient communication and the quali-
ty of their relationship can influence acceptance
of this new phase. In particular, the capacity to
build rapport and trust in the relationship con-
ditions the willingness of the patient to accept
and agree to the therapeutic prescription.
It is thus fundamental to assess the individual’s
degree of receptiveness, which depends on social,
cognitive and emotional variables, and affects the
capacity to understand the information provid-
ed. It is emphasized that information skills de-
pend not only on talking skills but also on the ca-
pacity to listen and understand.
Recommendations [AIII]:
- Offer the patient an interview in private;
- Guarantee the time necessary for comprehen-
sion, listening to and answering the patients’
questions;
- Explain in detail why it is important and/or nec-
essary to commence HAART;
- Inform the patient of the treatment options
with a discussion of the benefits and risks of
each approach.
VIRO-IMMUNOLOGICAL DIAGNOSTICS
The diagnosis of chronic HIV-1 infection is de-
fined by the presence of HIV-1 antibodies, con-
firmed by immunoblotting, according with the
official Consensus Document on the Policy of
Offering and Performing HIV Testing in Italy.
The plasma HIV-RNA concentration (viremia or
viral load) is used as a surrogate marker and serves
to forecast the risk of clinical progression of the in-
fection (prognostic marker) and assess the degree
of the therapeutic response (efficacy marker). Real
Time polymerase chain reaction (PCR) should be
considered the standard of care and its employ-
ment is strongly recommended [AI]. 
The main objective of combination antiretroviral
therapy in all patients is a reduction in viremia to
undetectable levels (undetectability), and the
maintenance of virological suppression for as long
as possible [AII]. To date, the guidelines suggest
using a limit value of greater than 50 copies/mL as
the criteria for virological failure assessment [AI].
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Level of evidence
LEVEL I
The data are obtained from at least one controlled, randomized study with sufficient power or from
a meta-analysis of controlled studies.
LEVEL II The data are collated from non-randomized studies or from cohort observational studies.
LEVEL III Recommendation based on case reviews or agreement among experts.
Degree of recommendation
A Highly recommended.
B Moderately recommended.
C Optional.
TABLE 1 - Degree of recommendation and level of evidence
The use of resistance tests is currently recom-
mended both for the choice of the first line ther-
apy [AII] and for the choice of alternative therapy
in the case of virological failure [AI].
The use of genotype assays is preferable to phe-
notype assays. Resistance assays should be inter-
preted with the use of viral genetic sequences with
management algorithms (virological interpreta-
tion). Ideally, resistance assays should be inter-
preted by clinicians with experience in utilizing
additional parameters in the assessment, such as
previous resistance tests, immunovirological and
therapeutic data (virological and clinical interpre-
tation). The best interpretation can be obtained in
the latter conditions [AII]. An additional assess-
ment with phenotype tests may prove useful for
patients with complex resistance situations [BIII].
The data available to date indicate the utility of
genotype or phenotype test for assessment of the
prevalent viral strain for the purpose of using
CCR5 antagonists [AII]. The simplicity of per-
formance, lower costs, and the reliability of the
test favour the genotypic assay [AII]. Quanti -
fication of the CD4+ lymphocyte count is an es-
sential prognostic marker. The CD4 count deter-
mines the indication for initiation of antiretroviral
therapy as well as the intiation or suspension of
prophylaxis of opportunistic infections [AI].
The CD4+ count should be repeated 1 month af-
ter commencing antiretroviral therapy and, sub-
sequently every 3-4 months in the stable phase. In
patients with unsatisfactory immunological re-
covery (<50-150 cells/µL per year), immunologi-
cal monitoring should be more frequent (2/3
months) [BI].
The percentage CD4+ count must be assessed to-
gether with the total CD4+ count as an immune
system function marker (CD4+ percentages be-
low 14% are associated with an increased risk of
opportunistic infections, approximately equiva-
lent to a CD4+ count of <20 cells/L) [AII].
WHEN TO START (Tables 2-4)
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Condition Recommendation for treatment Strength/evidence
Acute infection or recent seroconversion Not recommended
Acute infection with severe symptomatology Highly recommended* [AII]
*If therapy is initiated, inclusion in a controlled clinical study is recommended where possible [BIII]
TABLE 2 - When to start in patients with acute infection.
TABLE 3 - When to start in patients with chronic infection.
→
Clinical condition Lymphocyte 
T CD4+ count
Recommendation for treatment Strength/evidence
AIDS Any value Highly recommended [AI]
HIV-related diseases (group B of 1993
CDC definition)
Any value Highly recommended [AII]
Pregnancy Any value Highly recommended [AI]
HIV-associated nephropathy (HIVAN) Any value Highly recommended [AII]
Non AIDS-definining cancers Any value Highly recommended [AII]
HIV-associate neurocognitive disorders
(HAND)
Any value Highly recommended for MND or HAD.
Could be considered for ANI
[AII]
[BII]
Chronic HBV hepatitis requiring 
treatment*
Any value Highly recommended with agents active
against both HIV and HBV
[AII]
Elevated risk of secondary HIV 
transmission
Any value Moderately recommended only in the case
of a motivated patient
[BII]
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→ Clinical condition Lymphocyte T CD4+ count Recommendation for treatment Strength/evidence
Asymptomatic CD4+: ≤500 cells/µL Highly recommended [AII]
Asymptomatic CD4+: >350 cells/µL Highly recommended [AI]
Asymptomatic CD4+: >500 cells/µL Highly recommended in the presence of:
a) HIV-RNA >100.000 copies/mL
b) decrease of CD4+ >100 cells/µL per year
c) age >50 years
d) chronic HCV hepatitis 
Moderately recommended in the case of
highly motivated patients, considering the
reduction of risk of HIV transmission 
Moderately recommended in the case ofele-
vated cardiovascular risk:diabetes mellitus,
or previous cardiovascular event, or elevated
risk (>20%) in the next 10 years (estimate
with Framingham algorithm)
[AII]
[BII]
[BIII]
*In cases in which there is indication of HBV treatment by nucleotide/nucleoside analogues.
TABLE 4 - Timing of initiation of antiretroviral therapy in patients with AIDS or non-AIDS defining neopla-
sias (treatment Highly recommended [AI]).
Clinical condition Timing of initiation of antiretroviral therapy Strength/evidence (referred to
the timing of ommencement
of ARV therapy)
- Multifocal progressive
leukoencephalopathy
- HIV encephalopathy
-bWasting syndrome
- Enteritis from
Cryptosporidium or
Microsporidia
Immediate initiation highly recommended [AII]
Pneumonia from P. jiroveci Highly recommended initiation within 2 weeks of diagnosis [AI]
Tuberculosis ART initiation highly recommended during 
anti-tubercular therapy
- CD4 <50 cells/mm3: initiation recommended at 2 weeks from
starting of anti-tubercular therapy
- CD4 50-500 cells/mm3: initiation recommended within 2
weeks and 2 months of anti-tubercular therapy
- CD5 >500 cells/mm3: initiation to be established on individual
basis, according with cost-benefit evaluation
[AI]
[AI]
[AI]
[BII]
Cryptococcal meningitis Highly recommended initiation upon completion of induction
therapy for opportunistic infection
[AI]
Disease from atypical
mycobacteria
Optional, where possible, initiation within 4 weeks of treat-
ment for mycobacteriosis
[CIII]
CMV Disease Optional, where possible, initiation upon completion of in-
duction therapy for opportunistic infection
[CIII]
Patients with neoplasia Highly recommended immediate initiation and, in all cases
recommended prior to initiation of chemotherapy
[AII]
WHAT TO START WITH (Tables 5-9)
The choice of initial therapy in patients with HIV
must be tailored to:
a) Available data on the characteristics of the dif-
ferent agents and drug combinations (viro-
logical and immunological efficacy, confor-
mulation/convenience, toxicity and tolerabili-
ty, genetic barrier, prior clinical use).
b) Factors regarding the overall clinical status,
genetic factors, and characteristics of the pa-
tient including:
- Comorbidities (cardiovascular disease, he-
patic, renal disease, neurocognitive disor-
ders, psychiatric illness, concurrent infec-
tions and/or conditions such as drug
abuse/dependence, etc.);
- Potential adverse effects of the drugs used;
- Potential drug-drug interactions;
- Current or pregnancy potential;
- Genotype resistance test;
- Likelihood of adherence to treatment;
- Acceptability of regimen (number of pills,
number of administrations, assumption
modality);
- CD4+ lymphocytes count, if use of nevirap-
ine is considered;
- HLA-B 5701, advisable for all patients, is
mandatory if use of abacavir is considered.
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TABLE 5 - Conditions for classification of drugs and combinations.
Conditions for classification of drug/combination
Drug/combination satisfying the majority of the following conditions: it is considered “standard of care”; in at least one
randomized study it has shown to be at miniumum non inferior to “standard of care”; is compact/ convenient; it has a
favourable toxicity and tolerability profile; it has demonstrable extensive clinical use.
Drug/combination which does not satisfy all the first choice criteria but which may represent, in specific cases, the best
choice for a given patient (profiles of toxicity, pharmacological interactions with concomitant treatments).
Drug/combination considered efficacious, in cases where the patient does not tolerate or is unable to take first choice or
alternative drugs/associations.
To date, data in the scientific literature report, al-
most exclusively, the results obtained with com-
bination regimens consisting of: a backbone of
nucleos(t)ides (NRTI) and a base of a third drug
from another class. Indications for the choice of
drugs constituting the backbone may be deter-
mined on the basis of available coformulations
rather than the single drug.
TABLE 6 - Backbone nucleos(t)ide. First choice and alternatives.
Choices Pharmacological association
[strength/evidence]
Comment
First TDF/FTC* [AI] Superior to ZDV/3TC; co-formulated; QD.
Choice TDF/3TC* [BI] Only non-inferior to d4T/3TC, greater risk of resistances at failure compared
to TDF/FTC (but not by direct comparison); non co-formulated; QD.
ABC/3TC**[AI]*** Non-inferior to ZDV/3TC; non-inferior to TDF/FTC in presence of viremia
equal or lower than 100,000 copies/mL; inferior to TDF/FTC in presence of
viremia greater than 100,000 copies/mL when combined with ATV/r or EFV,
but not with LPV/r; lack of data on association with DRV/r and RAL; higher
CV risk; co-formulated; QD.
Alternative AZT/3TC [BI] Less effective; greater toxicity; lower genetic barrier; lack of data on asso-
ciation with DRV/r, ATV/r and RAL; co-formulated; non QD.
→
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Choices Pharmacological association
[strength/evidence]
Comment
Acceptable ddI/3TC or FTC**** [CI] ddI/3TC/EFV non-inferior to ZDV/3TC/EFV; greater toxicity than ddI, ab-
sorption significantly determined by food; non co-formulated; QD.
*Tenofovir should not be used in patients with renal insufficiency, and used with caution in patients with osteoporosis.
**Abacavir can only be used in HLA-B*5701 negative patients (screening recommended [AI]) and clinical HSR surveillance must be maintained in these pa-
tients; some studies have shown an increased risk of cardiovascular disease, even though two recent meta-analyses have not confirmed these results; do not
initiate concomitant treatment with nevirapine due to augmented risk of hypersensitivity reactions (HSR).
***ABV/3TC is highly recommended [AI] only in patients with HIV-RNA ≤100,000 copies/mL; in those with HIV-RNA >100,000 copies/mL it should be only
moderately recommended [BI].
****Didanosine + FTC/3TC only in association with EFV; with ATV excess of early virological failures; long-term mitochondrial toxicity (pancreatitis, peri-
pheral neuropathy, lactic acidosis), hepatic and endothelial (excess of myocardial infarction, non cirrhotic portal hypertension); not indicated in conjunction
with ribavirin (see HIV/HCV co-infection chapter).
→
TABLE 7 - Third drug, first choice.
In regards to choice of class for the third agent, consideration should be given to long-term efficacy data, the genetic
barrier to resistance and the long-term sequencing strategy.
Choices Drug [Strength/evidence] Comment
First Choice
EFV* (600 mg) [AI] Standard of care in the majority of randomized clinical studies in which it
has consistently shown equivalence or superiority; neuro-psychiatric
disturbances in the first 12 weeks administration; QD.
ATV/r (300/100 mg QD) [AI] Elevated tolerability. Non-inferior to EFV; non-inferior to LPV/r with lower
gastrointestinal toxicity and dyslipidaemia. Lack of data on the association
with ZDV/3TC; hyperbilirubinaemia; QD.
NVP** (400 mg) [BI] Criterion of non inferiority to EFV not reached; non-inferior to ATV/r (48
weeks) but greater toxicity; best lipid profile with respect to ATV/r; equivalent
to LPV/r (>48 weeks) but greater toxicity. Lack of data on the association
with ABC/3TC. BID; a new formulation of QD extended-release (XR) 400
mg tablet, which was demonstrated to be non-inferior to 200 mg BID
standard formulation when used in combination with TDF/FTC, has recently
approved by EMA.
DRV/r (800/100 mg QD) [BI] Limited use in naïve patients. Non-inferiority demonstrated only with respect
to LPV/r (virological superiority at 192 weeks); lack of comparative studies
with EFV or ATV/r. Lower gastrointestinal toxicity and dyslipidaemia than
LPV/r. Lack of data on the association with ABC/3TC and ZDV/3TC.
LPV/r*** (800/200 mg QD or
400/100 BID) [BI]
Inferior to EFV at 96 weeks. Standard of care in the majority of comparative
studies with other PIs; sole co-formulated PI; greater toxicity; 200 mg of
RTV; greater dyslipidaemia and gastrointestinal disturbances than DRV/r
and ATV/r; higher number of pills; BID (QD non-inferior to BID but only 48
weeks; QD inferior to DRV/r QD).
RAL (400 mg BID) [BI] Limited use in naïve patients; non-inferior to EFV with fewer adverse events
and dyslipidaemia at 152 weeks; Lack of data on the association with
ABC/3TC and ZDV/3TC; BID.
*EFV must not be used during first trimester of pregnancy, in women planning pregnancy or who may become pregnant due to lack of contraceptive use.
**NVP must not be used in women with CD4+ >250 cells/µL or in men with CD4+ >400 cells/µL (higher risk of hepatotoxicity and/or cutaneous rash); in the
first two weeks of therapy utilize the induction dose 200 mg/day. Some pilot studies indicate excess early virological failure with use of TDF+3TC+NVP QD:
this combination should therefore be avoided, with the TDF/FTC+NVP combination, both QD and BID were found efficacious in randomized studies. Use
with care in patients with hepatic viral co-infection.
***LPV/r 400/100 BID is the first choice therapy in pregnant women.
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TABLE 8 - Third drug, alternative, acceptable choices.
Choices Drug [Strength/ evidence] Comment
Alternative FPV/r* (700/100 mg BID) [BI] Non-inferior to LPV/r BID at 96 weeks with same toxicity profile; BID, 200
mg RTV and higher number of pills; QD not authorized in Italy.
Acceptable
SQV/r (1000/100 mg BID) [CI] Non-inferior to LPV/r (less hypertriglycerideamia), but with only a 48-week
follow-up; higher cardiac toxicity; 200 mg RTV; superior number of pills; BID.
ATV** (400 mg QD) [CI] Non-inferiority study with small sample size does not confirm non-inferiority
to ATV/r at 96 weeks; greater virological failures; studied only in association
with d4T+3TC.
Maraviroc*** [CI] Non-inferior to EFV only in one post-hoc analysis; BID; studied only with
AZT+3TC.
*FPV/r 1400/200 mg QD [BI]) 48 week studies compared with NFV, daily dosing not authorized in Italy; FPV/r 1400/100 mg QD [BI]) small study, dosing not
authorized in Italy
**ATV without ritonavir not authorized in Italy; not to be used in any case without ritonavir booster when in concomitant use with tenofovir (except where
plasma levels can be verified by TDM, see specific chapter) and/or efavirenz. The panel has decided to await new data before making a definitive recom-
mendation. 
***Maraviroc not registered in Italy for first line use. In naïve patients it demonstrated non-inferiority at 96 weeks against efavirenz in only one post-hoc analy-
sis. The agent was studied exclusively in association with AZT+3TC at a dosage of 300 mg BID. Good efficacy is to be expected with a non-thymidine analo-
gue backbone. Nevertheless, the panel has decided to await new data before making a definitive recommendation.
TABLE 9 - Comparison of virological and immunological efficacy, convenience and genetic barrier of different
antiretroviral regimens used in the treatment of naïve patients (first and alternative choice).
NUCLEOS(T)IDIC BACKBONE
Rank Virological
efficacy
Immunological
efficacy
Compactness/convenience
(number of pills and
administrations, co-formulation)
Extensive
clinical use
Genetic barrier (lower
frequency of resistance
at failure)
1 TDF/FTC
TDF+3TC
TDF/FTC
TDF+3TC
ABC/3TC
TDF/FTC
ABC/3TC
TDF/FTC
TDF+3TC
ABC/3TC
AZT/3TC
TDF/FTC
2 ABC/3TC* AZT/3TC TDF+3TC ABC/3TC**
TDF+3TC
AZT/3TC
3 AZT/3TC AZT/3TC
THIRD DRUG
1 EFV
ATV/r
DRV/r
RA
ATV/r, LPV/r,
DRV/r, FPV/r
EFV, NVP-XR*** EFV
LPV/r
ATV/r
NVP
DRV/r
ATV/r
LPV/r
FPV/r
2 LPV/r
FPV/r
NVP
EFV, NVP, RAL ATV/r, DRV/r FPV/r
DRV/r
EFV
NVP
RAL
3 NVP*, RAL, LPV/r RAL
4 FPV/r
*If HIV-RNA before starting therapy <100,000 copies/mL, rank 1. *Lower risk of selecting resistance associated mutations for FTC compared to 3TC, espe-
cially if HIV-RNA is >100,000 copies/mL. *Nevirapine extended release (XR) with single tablet QD administration
HOW TO CONTINUE AFTER VIROLOGICAL
SUPPRESSION: STRATEGIES FOR 
OPTIMIZING CART (Tables 10, 11)
The long-term treatment prospects and the avail-
ability of more compounds, more manageable
and affected by different toxicities, enhance a tai-
lored approach to cART management in order to
maintain viroimmunological efficacy. Optimizing
cART in a patient with persistent suppressed HIV
viremia indicates the best strategies of therapeu-
tic switching, with different purposes and ra-
tionale, but with mutual principles. The main rec-
ognized strategies are:
1. A reduction in the number of ARV drugs
(schematic simplification);
2a.A reduction of daily doses and pill burden, but
still in a triple cART regimen (management
simplification);
2b.Other switching strategies with a triple drug
combination, not included in the above con-
ditions.
Therefore, the potential benefit and risk of tai-
lored strategies should be accurately evaluated
and discussed, and targeted to the needs of the
single patient. The main reason leading to this
choice may be:
- Documented toxicity.
- Presence of side-effects.
- Prevention of long-term toxicity (pre-emptive
switch).
- Current therapy may worsen co-morbidities or
clinical manifestations linked with aging.
- Interactions with other drugs.
- In dication to treat other infections (TB, HBV,
HCV, etc.).
- Need to improve patient adherence
- Planned pregnancy
- Request of the patient
- Current regimen no longer recommended.
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TABLE 10 - The reduction of the number of ARV drugs (schematic simplification).
TABLE 11a - The reduction of daily doses and pill burden (management simplification)
Type of switch Aims Other potential benefits Potential disadvantages Degree recomm.
level of evidence
From three drugs to
LPV/r monotherapy
(400/100 mg BID)
Reduce toxicity Reduce NRTI toxicity
and possible previous
NNRTI toxicity
Increase in pill burden/number of do-
ses except for current 2NRTI + LPV/r
regimens; gastrointestinal and meta-
bolic side-effects; increased CVD risk
in the long-term; lower virological ef-
ficacy than triple therapy; possible li-
mited efficacy in reservoirs; con-
traindicated in HBsAg+
[BI]
From three drugs to
DRV/r monotherapy
(800/100 mg QD)
Reduce toxicity;
simplifying from
BID
Reduce NRTI toxicity
and possible previous
NNRTI toxicity; sim-
plifying from BID
Virological efficacy not certainly non-
inferior than triple therapy; possible
limited efficacy in reservoirs; con-
traindicated in HBsAg+
[BI]
Type of switch Aims Other potential
benefits
Potential
disadvantages
Degree recomm.
level of evidence
From single compounds to
fixed-dose combinations
Improve adherence
and quality of life
Coformulation None [AII]
From NVP BID a NVP-XR
QD
Improve adherence
and quality of life
Lower pill burden
and number of doses
None [AI]
From PI/r to EFV Reduce toxicity Lower GI side-effects,
coformulation
Neuropsychiatric side-
effects; lower genetic
barrier
[AI]
→
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TABLE 11b - Other switching strategies.
Type of switch Aims Other potential
benefits
Potential disadvantages Degree recomm.
level of evidence
From PI/r to NVP Reduce
toxicity
Lower GI and meta-
bolic side-effects
Cutaneous rash and liver enzyme elke-
vations in the short term; lower genetic
barrier
[AI]
From PI/r to raltegravir Reduce
toxicity
Lower GI and meta-
bolic side-effects
Lowere genetic barrier; no-inferiority
not achieved in a study; BID regime;
not recommended in previously docu-
mented NRTI failure; use only after at
least 6 months of virological suppres-
sion 
[BI]
From enfuvirtide to ralte-
gravir Reduce toxicity
Reduce
toxicity
Reduce cutaneous
adverse reactions in
site of injection;
more manageable;
improve QoL
None [AI]
Type of switch Aims Other potential benefits Potential
disadvantages
Degree recomm.
level of evidence
From tymidine
NRTI or ddI to
TDF or ABC
Reduce lipoatrophy
and other toxicities;
Lower pill burden and
number of doses
Reduce toxicity; increase conve-
nience; improve adherence
[AI]
From TDF to ABC Reduce specific toxi-
city
Lower renal and bone toxicity Increase dyslipidemia [AIII]
From ABC to TDF Reduce specific toxi-
city
Lower dyslipidemia Reduce renal and bo-
ne toxicity
[AIII]
From EFV to NVP Reduce specific toxi-
city
Lower dyslipidemia; better CNS
penetration/effectiveness
Cutaneous rash and li-
ver enzyme elevation in
the short term; no co-
formulation
[AIII]
From NVP to EFV Reduce specific toxi-
city
Coformulation Increae dyslipidemia;
neuropsychiatric side-
effects 
[AIII]
From LPV/r to
ATV/r or DRV/r
QD
Reduce specific toxi-
city
Lower dyslipidemia and GI side-
effects; Lower pill burden and
number of doses
No RTV coformula-
tion; hyperbilirubine-
mia with ATV/r
[AI]
From DRV/r BID
to DRV/r QD
Simplification Simplification (lower pill burden
and number of doses); lower
dyslipidemia
In case of lack of DRV
resistance-associated
mutations only
[AI]
From ATV/r to
ATV
Reduce specific toxi-
city
Improve hyperbilirubinemia,
slight improve of dyslipidemia
Unboosted ATV not
approved in Italy; lo-
wer genetic barrier;
not indicated in asso-
ciation with TDF or
PPI
[BI]*
*Indicated in patients with RTV intolerance; advisable TDM monitoring.
→
MANAGEMENT OF THERAPEUTIC FAIL-
URE (Tables 12-15)
Despite the efficacy of current antiretroviral treat-
ment, a measurable proportion of patients expe-
rience therapeutic failure due to a suboptimal vi-
rological response (virological failure), unsatis-
factory immunological response (immunological
failure) and, to a lesser extent, clinical progres-
sion (clinical failure). Clinical failure is defined
by the onset of HIV-related clinical events in pa-
tients on antiretroviral therapy for at least three
months, after the exclusion of immune reconsti-
tution syndrome. Immunological failure may be
defined as a failure to recover and/or maintain (a
normal?) CD4+ lymphocyte count despite viro-
logical suppression. Virological failure is defined
by lack of suppression of HIV viremia to values
below 50 copies/mL of plasma HIV-RNA (unde-
tectability) 24 weeks after treatment initiation or
as a rise in viral replication (rebound), confirmed
by two consecutive measurements in patients
who had previously achieved complete viral sup-
pression.
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TABLE 12 - Recommendations for accurate, early assessment of virological failure
TABLE 13 - Useful considerations when deciding on a new antiretroviral regimen in patients with virological
failure.
Condition Recommendation
Patients with residual low-level viremia
(1-49 copies/mL).
Documentation of residual low-level viremia no longer satisfies the criteria for
diagnosis of virological failure. On the basis of the data available there is no in-
dication for modification of the current regimen [AIII].
Patients with viral blips (50-1000
copies/mL), isolated, non consecutive,
alternating with undetectable viral load
measurements.
Investigate adherence, potential pharmacological interactions, consider possi-
ble variability in the HIV-RNA test. Modification of the antiretroviral regimen
is not necessary [AII].
Patients with viral blips (50-1000
copies/mL) persistent, consecutive,
progressively rising, genotype non
determinable.
There is no clear guidance in the literature on the appropriate management of
these patients, although active, persistent viral replication is evident. It is rea-
sonable to undertake genotyping and consider modification of the current an-
tiretroviral regime [BII].
Patients with viremia >1000 copies/mL
and absence of mutations in the
genotypic resistance test performed.
Investigate adherence, consider resumption of the same regimen monitoring
the virological response after 4 weeks and repeating genotype for early identi-
fication of emergence of resistant viral variants [BIII]. In patients on unboo-
sted protease inhibitor therapy, consider immediate introduction of low doses
of ritonavir as a pharmacokinetic booster [BII].
Patients with viremia >1000 copies/mL
and mutations in the genotype test
performed.
Modify the current antiretroviral regime [AII].
In a patient with virological failure, a new antiretroviral regimen must include at least 2, preferably 3 fully active drugs [AII].
In the case of first failure, it is advisable to choose drugs from classes that have not been used before.
With standard tests, the most recent genotype may not detect certain archived mutations. All of the patient’s previous ge-
notypic and phenotypic assays must be taken into consideration (when deciding on the appropriate choice of a new regi-
men); even agents to which the patients has never been exposed may not be fully active 
Consider all potential negative pharmacological interactions with the new regimen; a drug never taken before is not always
a fully active drug when included in a new therapeutic regimen.
In patients who do not have three fully active drugs available, consider that some antiretroviral drugs (e.g. NRTIs) can con-
tribute to the efficacy of the new regimen with partial antiviral activity, albeit in the presence of resistance, while for other
drugs (e.g.: enfuvirtide, NNRTIs, raltegravir) no partial antiviral activity has been demonstrated.
Certain factors are associated with a more favourable virological response, irrespective of the type of regimen used (e.g.:
low-level viremia and elevated CD4+ at the time of regimen modification, use of a drug from a new class, increasing num-
ber of active drugs and, therefore, GSS and PSS).
ADHERENCE AND QUALITY OF LIFE
Optimal adherence to antiretroviral drugs must
always be pursued to obtain and maintain both
the viro-immunological and clinical success of
treatment [AII]. High-level adherence to anti-
retroviral drugs has a pivotal role in reducing the
risk of HIV transmission, especially in HIV
serodiscordant couples [AII].
In the clinical setting, the patient’s self-reported
adherence, if investigated in a non-judgmental,
routinized and structured fashion, is the most
suitable method to measure adherence and in-
stitute longitudinal monitoring for early identifi-
cation of specific barriers to adherence [AII].
Other objective methods, such as assessment of
antiretroviral refill dates, pill counts, and plasma
drug concentration monitoring may be utilized
as adjunctive information to assess patient ad-
herence [BII].
The quality of the physician-patient relationship,
the role of nursing staff, a multidisciplinary ap-
proach to care, together with the contribution of
peer individuals, are all relevant for both adher-
ence monitoring and supporting the optimal as-
sumption of antiretroviral drugs [BII]. 
Simplified antiretroviral dosing with fixed-dose
combinations has been shown to promote ad-
herence to the antiretroviral therapy [AI].
In the clinical setting, it is recommended to in-
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TABLE 14 - Recommended sequential regimens as determined by failed first line therapy.
First regimen Second regimen
2 NRTI + NNRTI 2 NRTI* + PI/r
2 NRTI + PI/r 2 NRTI* + PI/r*
2 NRTI + PI 2 NRTI* + PI/r*
3 NRTI *1 NRTI + 1 PI/r + 1 NNRTI
*2 NRTI + 1PI/r
1PI/r + 1 NNRTI
1PI/r + 1 INI
1 PI/r + 1 CCR5 inhibitor
* = Chosen on the basis of resistance assay.
TABLE 15 - Management of virological failures subsequent to the first and use of new classes of drugs.
Situation Choice
Availability of at least 2 active drugs* Change the regimen as soon as possible.
If possible include high genetic barrier drugs in the regimes
(new boosted protease inhibitors) in combination with other
agents of different classes chosen on the basis of resistance
test results.
Availability of 1 active drug only* The most fragile situation, the decision to modify antiretro-
viral therapy must take into account the immediate risk of
clinical progression, the risks associated with maintenance
of the current regimen and the probability of virological suc-
cess of the subsequent regime in the medium term. A main-
tenance regimen may be reasonable while awaiting the avai-
lability of another active drug.
Absence of active drugs Determine the optimal maintenance regimen.
*of all agents available, in the market or in early access protocols.
vestigate the presence of psychiatric disorders
and depression in order to consider a specific
treatment. Self-reported symptoms should be in-
vestigated, and if associated with therapy, a treat-
ment modification should be considered [BII].
The observation of non-adherence behaviour re-
quires intervention strategies [AI]. Identification of
the most appropriate intervention is based on the
experience of the medical-nursing staff and is based
on a “tailored” and multidisciplinary approach
combining strategies related to antiretroviral man-
agement with educational and behavioural inter-
vention providing support to the patient [BI].
The improvement in quality of life related to
health is a primary objective of antiretroviral ther-
apy. It is therefore necessary to include the use
of patient-centered strategies in the clinical care
of the patient. Ongoing monitoring of patient-
centered outcomes is recommended in clinical
centres, with the same frequency as standard clin-
ical examinations [AII], and using tools for
screening of depression (e.g. CES-D and CES-
D10) could be useful.
PHARMACOLOGICAL MONITORING 
(Tables 16-17)
Definition of TDM
Therapeutic monitoring of plasma drug concen-
trations (TDM - Therapeutic Drug Monitoring) is
a useful adjunct for individualizing therapy, espe-
cially when utilizing agents with a clear correla-
tion between concentration and therapeutic and/or
toxic effect, a limited therapeutic margin and wide
inter-individual pharmacokinetic variability.
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TABLE 16 - Clinical scenarios of possible use of TDM.
Scenario Strength/evidence
Significant alterations of gastroenteric, hepatic or renal function [CIII]
Pregnancy LPV/r, SQV/r [CIII]
Previous failures with resistant virus PI with use of IQ [CII]
Concentration-correlated toxicity IDV/r [BII], EFV [CII], ATV [CIII]
Non-conventional dosing schemes [CIII]
Treatment adherence [CIII]
Pharmacological interactions [BIII]
Interactions
The management of pharmacological interactions
is the clearest clinical indication for use of TDM
[BIII]. Different antiretroviral drug types or class-
es (NNRTI, IP, MVC) are associated with signifi-
cant pharmacological interaction as they are, to
various extents, substrates, inhibitors or inducers
of the P450 cytochrome (in particular the CYP3A4
isoenzyme, but also CYP2B6, CYP2C9, CYP2C19)
and P glycoprotein. The N(t)RTI, ENF and RAL
have differentiated metabolic profiles and there-
fore have limited or low potential for interaction.
Refer to specific sites (first of all www-hiv-drug-
interactions.org) for an exhaustive discussion of
information pertaining to management of phar-
macological interactions.
TABLE 17 - Principles of TDM use in the management of pharmacological interactions
NNRTI, PI and MVC have a higher risk of pharmacological interaction as substrates, inhibitors or inducers of the P450
cytochrome system and P glycoprotein.
N(t)RTI, ENF and RAL have limited or low potential for interaction.
The extent of a known interaction may be unpredictable in individual cases [CIII].
The sum of several simultaneous pharmacological interactions is often difficult to predict [CIII].
The extent of the interaction may have different specific weights and effects depending on the clinical variables of the sin-
gle case [CIII].
A pharmacological interaction may be unpredictable and must be suspected in the case of unexpected clinical and thera-
peutic events [CIII].
PHARMACO-GENETICS (Table 18)
NON-INFECTIOUS COMORBIDITIES 
(Tables 19-23)
General principles
The non-infectious pathologies associated with
HIV infection are the most frequent symptomatic
manifestations in HIV-infected persons on anti-
retroviral therapy. 
These derive from the interaction of risk factors
relative to host, virus, and drug [BII]. Their clin-
ical relevance affects:
- prognosis [AI];
- choice or modification of the antiretroviral
drugs [AII];
- multidisciplinary patient management [AIII].
These comorbidities manifest in progressive or-
gan damage leading to end-stage organ failure:
- End-stage organ failure determines patient
morbidity and mortality [BII].
- They may be diagnosed by functional or struc-
tural tests with the capacity to detect disease in
the asymptomatic stage [BII].
- Multiple comorbidites are physiological during
aging and HIV infection is associated with a
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TABLE 18 - Principles of use of genetic testing for the HLA-B*5701 allele
Highly recommended before starting antiretroviral therapy containing ABC [AI].
In negative patients clinical monitoring is recommended in all cases within the first 6 weeks of treatment as the possibi-
lity of abacavir associated HSR cannot be completely excluded [CIII].
The test should be performed at baseline in all newly infected patients in order to register data in the patients’ clinical re-
cords for future use [CIII].
process of premature aging the pathogenetic
mechanisms of which are only partially under-
stood.
Risk factors associated with HIV infection are re-
lated to genetic and environmental factors which,
in turn, affect lifestyle. The recognition and cor-
rection of deleterious lifestyle choices are the most
effective interventions for the prevention and
treatment of non-infectious comorbidities. Factors
related to HIV infection include immunological
damage (immunodeficit and immune deregula-
tion) and by a state of systemic inflammation as-
sociated with accelerated cellular and organ senes-
cence. Undetectable HIV viremia does not elimi-
nate the excess risk associated with HIV disease.
Co-infections (hepatitis viruses, herpes viruses,
etc.) are additional risks for non-infectious pathol-
ogy. The increased risk of specific organ damage
associated with cumulative or current antiretro-
viral exposure occurs through mechanisms which
have not been fully elucidated.
The table below shows the main risk factors for
non-infectious comorbidites associated with HIV
infection considered in these guidelines [AIII].
TABLE 19 - Risk factors for non-infectious comorbidities associated with HIV infection
Heart Kidney Bone Liver Cancers Lipodystrophy Sexual dysfunction
Age ✔ ✔ ✔ ✔ ✔ ✔ ✔
Sex ✔ ✔ ✔ ✔
Diabetes ✔ ✔ ✔ ✔ ✔ ✔
Hypertension ✔ ✔ ✔
Dyslipidaemia ✔ ✔ ✔ ✔ ✔
Family history ✔ ✔ ✔ ✔ ✔
Waist circumference ✔ ✔ ✔
Vit D/PTH ✔ ✔ ✔ ✔ ✔ ✔ ✔
Smoking ✔ ✔ ✔ ✔ ✔ ✔ ✔
CD4+ ✔ ✔ ✔
HIV VL ✔ ✔
ARV ✔ ✔ ✔ ✔ ✔ ✔ ✔
Screening for non-infectious comorbidities
associated with HIV infection
Screening for non-infectious comobidities is an
integral part of comprehensive clinical assess-
ment in all HIV-infected patients [AII]. Screening
must be periodic and should be repeated in all
patients before starting antiretroviral therapy or
when changing antiretroviral management strat-
egy [AIII].
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TABLE 20 - Screening strategies for non-infectious comorbidities associated with HIV infection.
Assessment At HIV
diagnosis
Before start 
of cart
Follow-up
freq. with cart
Comments
Anamnesis
Prior and current non-
infectious pathologies.
+ + Assessment to be repeated if patient
transferred to other care centre.
Family history
(e.g. early
cardiovascular disease:
indicates cardiovascular
events, diabetes,
hypertension, chronic
kidney disease)
+ + Early cardiovascular disease-
cardiovascular events in first degree
family members: males <55 years,
females <65 years
Concomitant
pharmacological
therapies
+ + at each visit
Current lifestyle:
- Use of psychotropic
medications or drugs
(alcohol, smoking, illicit
drugs) 
- diet
- physical activity
+ + every 6-12
months
More frequent discussion with the
patient of healthy lifestyle and
habits is recommended.
Toxic alcohol damage is expressed
in consumption exceeding 30
grams/day in males and 20 grams in
females)
Body
composition
Measurement of body
mass index and waist
circumference
+ + once a year
Clinical assessment of
lipodystrophy
+ + once a year Objective examination for
lipodystrophy must be segmental,
where possible using assessment
methods for the diagnosis of the
lipo-atrophy and lipo-hypertrophy.
The objective tools for of
measurement of lipo-atrophy and
lipo-hypertrophy include DEXA
(with measurement of the fat mass
in the limbs), abdomen CT (with
measurement of visceral
subcutaneous fat) and
ultrasonography assessment of the
depth of subcutaneous fat in the
limbs and cheeks [BIII].
→
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Assessment At HIV
diagnosis
Before start 
of cart
Follow-up
freq. with cart
Comments
Sexual and
reproductive
health
Anamnesis of sexual life:
- Safe sex
- Sexual dysfunction
- Reproductive
counseling
+ + once a year Sexual dysfunction can be
investigated by self-reported
questionnaire.
Periodical gynecologic evaluation is
advisable.
Cardio-
vascular
disease
Assessment of overall
risk
+ + once a year Using algorithms such as
Framingham
(http://hp2010.nhlbihin.net/atpiii/
CALCULATOR.asp?usertype=prof),
or o DAD 5 Year Estimated Risk
calculator
(http://www.cphiv.dk/TOOLS/DADRi
skEquations/tabid/437/Default.
aspx)
Framingham risk score is
appropriate in men older than 50
yrs, and in women aged >40 yrs.
ECG is indicated for risk evaluation
in patients with hyperthension and
for assessment of cardiac
conduction in patients taking
protease inhibitors.
Individualized clinical
evaluation
+ + once a year
Hyperten-
sion
Blood pressure + + once a year
Dyslipida-
emia
TC, HDL Col, LDL Col,
TG
+ + once a year
Diabetes
mellitus
Serum glucose + + every 6-12
months
Consider oral glucose load test if
fasting glycaemia values rare
repeatedly between 110-125 mg/dl
Liver
disease
Risk assessment, 
ALT/AST, GGT
+ + every 3-6
months Frequency of checks must increase
before and during treatment with
hepatotoxic drugs
Liver ultrasonography
in patients with liver
enzyme elevation
+ + once a year
Kidney
disease
Risk assessment + + once a year
eGFR estimated with
MDRD or Cockroft-
Gault CKD-EPI
calculators
+ + every 12
months
Frequency of checks must increase
in the presence of risk factors for
chronic kidney disease and/or
before and during treatment with
nephrotoxic agents
Urinalysis for
proteinuria and plasma
phosphate levels 
+ + once a year See above for the frequency of
assessment. 
With proteinuria ≥1 +/- eGFR <60
ml/min measure protein/creatinine
in urine is advisable.
In patients starting a tenofovir-
containing regimen the initial
assessment including plasma
phosphate level must be carried out
after 4 weeks and every 3-12 months
thereafter.
→
→
Assessment of the risk of toxicity associated
with antiretroviral drugs
There are short- and medium-term toxicities
linked with the use of antiretroviral drugs.
Continuous exposure to antiretroviral therapy re-
inforces the need for post-marketing pharmaco-
logical surveillance [BII]. HIV infection control
through virological suppression is a required for
reducing drug-related toxicities [AI].
The principal toxicities attributable to different
classes and single drugs, based on data from reg-
istration studies or significant cohort studies, are
listed below.
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Assessment At HIV
diagnosis
Before start 
of cart
Follow-up
freq. with cart
Comments
Bone disease
Height measurement + + every 2 years In the case of a loss of more than
3cm in height, lateral spine Xrays
(thoracic) are indicated [AII].
Assessment of major
risk factors for
osteoporosis
+ + once a year Major risk factors: hypogonadism,
family history of fractures, BMI <19
kg/m2, hypovitaminosis D, smoking,
sedentary lifestyle, history of low
impact fractures, advanced age,
female gender, menopause or
amenorrhea, habitual alcohol excess
(>3 units/ day), steroids exposure
for >3 months.
Estimate of risk of
fractures in subjects
aged >40 years with
FRAX®
+ + every year Employing algorithms as FRAX®
(http://www.shef.ac.uk/FRAX/
tool.jsp)
Vitamin D dosage + + every year To be performed annually,
preferably in autumn or spring, if
risk factors or diseases related to
ospeoporosis are present (chronic
kidney disease, rheumatoid artritis,
chronic inflammatory bowel
diseases, hyperparathyroidism)
[AII].
Examination of bone
mineral metabolism 
(at least 1 re-absorption
marker and 1 deposit
marker) and PTH
+ + every year [AII]
DXA scan of the lumbar
spine and hip or
densitometry surrogate
tests
+ every 2 years DXA is indicated when, in addition
to HIV, at least 2 of the major risk
factors for osteoporosis are present
[BIII]
DXA has the advantage of providing
objective anthropometric
measurements for the diagnosis of
lipodystrophy [BIII]
→
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TABLE 21 - Principal toxicities attributable to different ARV classes and single drugs.
Rash -
hypersen-
sitivity
Gastro-
intestinal
Hepatic
toxicity
Cardio-
vascular
Bone/
muscle
Renal 
toxicity
Nervous
system
Lipody-
strophy
Metabolic
alterations
NRTI X X X
AZT X X X X X X
d4T X X X X X
ddI X X X X X
3TC
FTC
ABC X X X
TDF X X
NNRTI X
EFV X X X X
NVP X X
ETV X
PI X X X X X
IDV X X X X X X
SQV X
LPV X X X
FPV X X X X
ATV X X
DRV X
TPV X X X
Fusion 
inhibitors
ENF X
Integrase 
inhibitors
RAL X X
CCR5
Inhibitors
MVC X
General principles of treatment 
of non-infectious comorbidities
Evaluation of the risk of non-infectious comor-
bidities is based on progressive steps which may
need multispecialistic intervention:
- Step 1: assessment of traditional risk factors for
each non-infectious comorbidity. HIV represents
an independent risk factor for organ disease [AII].
- Step 2: stratification of clinical risk by diag-
nostic algorithms. When specific HIV-related
risk estimators are lacking, risk estimators of
general population could be used [AII].
- Step 3: the vulnerability of single patients
should be evaluated.
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TABLE 22 - Principles of intervention for main modifiable factors.
Interventions Principles
Smoking cessation Identify the motivational aspects for discontinuing smoking
The short-term benefits are:
- monetary savings
- increased perception of flavours
- improved skin trophism
- reduction of dyspnea.
The long-term benefits are:
- prevention of chronic obstructive pulmonary disease (COPD)
- coronary artery disease and stroke
- lung cancer
Instruments of proven utility for smoking cessation:
- refer to specialist anti-smoking centres
- nicotine substitute products
Discuss the risk of smoking relapse after cessationalso in the long-term , considering the process
of fighting smoking craving.
Diet Nutritional counselling:
- Maintain the balance between calorie input and energy consumption
- Moderate intake of saturated fats, cholesterol and refined carbohydrates
- Limit alcohol consumption to <20 g/day for females and <30 g/day for males
- Reduce total fat intake to <30% and cholesterol intake to <300 mg/day
- Consume many vegetables, fruit and fibre rich cereals
- Introduce fish, poultry (no skin) and lean meat to the diet
- Avoid alternating periods of strict diet and binges (so-called yo-yo dieting)
Specialist nutritional intervention reserved for obese patients and those with wasting syndrome.
Reduction of alcohol intake to less than 20-40 mg daily, especially in patients with liver diseases,
low adherence to antiretroviral therapy, poor immunological response, cancers, previous
tuberculosis, diarrhea.
Physical therapy An active lifestyle is fundamental to prevent and treat obesity, hypertension and diabetes.
Regular aerobic activity (e.g. 30 minutes of sustained walking at least 5 days a week) is useful to
reduce the accumulation of visceral fat, maintain muscular strength and prevent osteoporosis.
It is necessary to verify that the physical activity undertaken satisfies cardio-fitness requirements
(adequate duration, adequate increment of cardiac frequency)
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TABLE 23 - Identification and management of patients at high risk of cardiovascular disease.
Identification of patients with high cardiovascular risk through:
1. Estimation of the risk of cardiovascular disease (CVD) with risk prediction charts or algorithms
2. Individual clinical assessment
Advise on diet and lifestyle in all patients
Consider individualized modification of ARV therapy in patients with high CV risk
Identification of modifiable risk factors
Smoking Blood pressure Coagulation Glucose Lipids
Start treatment if:
systolic blood pressure (SBP)
≥140 or diastolic blood
pressure (DBP) ≥90 mmHg
(especially if 
10-year CVD risk ≥20%)
Start
treatment if:
CVD present
or age ≥50
and 10-year
risk ≥20%
Confirm
diagnosis of
DM and
start therapy
if: HBA1c
≥6.5%
Start treatment therapy if:
CVD present or type II DM II or TC:HDL
ratio >6 or 10-year risk ≥20%
Target Target - N/A Target
HBA1c
<6.5%
Target
If DM or CVD
or CKD +
proteinuria. 
BP <130/<80
Absence of
DM and
CVD, BP
<140/<90
Treatment
with
acetylsa-
licylic acid
75-150 mg/d
Optimal Standard
TC 155 mg/dL 190 mg/dL
LDL 80 mg/dL 115 mg/dL
TABLE 24 - Prevention and management of patients at high risk of hepatic damage
Prevention Management
In the case of co-infection with Hepatitis C virus evaluate
the possibility of treating this condition: treatment of
Hepatitis C reduces the risk of “drug-induced liver injury”
(DILI). Refer to the specific section of the guidelines for ma-
nagement of these cases.
In obese patients and those with metabolic syndrome, ul-
trasonography to assess the presence of NAFLD. Computed
tomography (CT) and magnetic resonance imaging (MRI)
may be used for further diagnostics in selected cases.
Modifying predisposing factors for NAFLD such as hypergly-
caemia, dyslipidaemia, arterial hypertension, abdominal obe-
sity, may reduce the evolution of liver disease and prevent
drug-related hepatotoxicity. Among the modifiable predi-
sposing factors consider HCV infection with genotype 3,
which is associated with hepatic steatosis and an increased
risk of drug-associated liver damage.
In patients starting nevirapine: check liver enzymes at base-
line, every two weeks for the first month, each month for the
first three months, then every three months.
Reassessment of current antiretroviral therapy: because li-
ver damage - above all when linked with mitochondrial to-
xicity - may be clinically silent, it is important to evaluate
the possibility of substituting older generation NRTI if pre-
sent in current therapy.
Exclude other causes of liver enzyme elevation, in particular
alcohol abuse, presence of co-infections with hepatitis viru-
ses and interruption of treatment with 3TC, FTC and TDF
in patients with chronic hepatitis B.
In the case of liver enzyme elevation, if the patient is sympto-
matic with a clinical hepatitis or a concomitant rise in bili-
rubin, immediately discontinue all current treatment. Upon
normalization, consider the use of antiretroviral drugs with
minimal hepatic toxicity.
In the asymptomatic patient, consider suspension of the drug
in all patients with liver enzyme elevation 5-10 times the nor-
mal level.
In the presence of both augmented liver enzyme elevation
and of symptoms drug hypersensitivity reaction, suspend
current treatment immediately. Re-administration of the sa-
me therapy may prove fatal.
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TABLE 25 - Prevention and management of patients at high risk of bone disease.
Prevention Management
Lifestyles beneficial for the prevention and treatment of
osteoporosis include: physical activity, daily consumption of
1 g of calcium and Vit D 800 UI/day with a weight loss and
malabsorption prevention diet (BMI <18.5), smoking cessa-
tion and decreased alcohol consumption.
A height loss of more than 3 cm suggests a diagnosis of ver-
tebral fracture.
The classic risk factors for osteoporosis include: hypogona-
dism, family history of fractures, BMI <19 kg/m2, hypovita-
minosis D, smoking, sedentary lifestyle, low impact fractures,
advanced age, female gender, menopause and/or amenor-
rhea, habitual alcohol consumption of >3 units/day, steroids
exposure for >3 months.
Plasma levels of 25-OH vitamin D should be checked in all
patients preferably in autumn and spring. Considering that
in some individuals (especially those with very low 25-OH
vitamin D plasma levels) regular nutritional supplementa-
tion may not be able to obtain optimal level, retesting plasma
levels after 6 months from nutritional supplementation is
advisable.
Correct assessment of the bone structure cannot be separa-
ted from a study mineral metabolism.
The bone toxicity of tenofovir exceeds that of other antire-
trovirals, and is expressed in particular in the first 12 months
of therapy, especially if used in association with PI/r and in
pre-treated subjects: in the case of alterations in renal func-
tion and/or of bone metabolism, and in the presence of va-
lid, efficacious alternatives, it is advisable to assess options
for treatment modification.
There are no antiretroviral therapy simplification strategies
of proven efficacy in the prevention or treatment of osteo-
porosis.
For correction of hypovitaminosis D, cholecalciferol must
be administered: two consecutive oral administrations of
300,000 UI each, preferably in spring and autumn, followed
by a maintenance dose of oral cholecalciferol of 7,000 UI
each week. If possible, control of 25-OH vitamin D levels af-
ter 6 months from nutritional supplementation is advisable,
in order to assess reaching of optimal plasma levels.
In the case of hypovitaminosis, testing of plasma calcium,
phosphate, alkaline phosphatase and PTH levels is indica-
ted.
Always supplement with calcium in the case of low alimen-
tary intake.
TABLE 26 - Prevention and management of patients at high risk of lipodystrophy
Prevention Management
For all patients with HIV infection, collection of anthropo-
metric data including BMI, waist circumference, objective
evaluation of adipose tissue redistribution is indicated, pos-
sibly with questionnaires.
A correct diet and physical activity can reduce the accumu-
lation of visceral fat and lead to improvement in insulin sen-
sitivity and blood lipids, especially in obesity associated with
lipo-hypertrophy. This intervention may, however, exacerba-
te subcutaneous lipo-atrophy.
Lipodystrophic mixed phenotype or due to central accumu-
lation has been associated with an increase of overall mor-
tality and to an increased risk of cardiovascular events.
Modification of antiretroviral therapy, replacing thymidine
analogues, is the only measure proven to partially re-esta-
blish subcutaneous fat, with an average increase in total fat
in the limbs of up to 400-500 g/year. The option of NRTI-spa-
ring regimes is also available.
Replace d4T or ZDV with abacavir (ABC) or tenofovir (TDF).
The potential risk of toxicity linked with the use of these
drugs must be taken into consideration.
Avoid use of stavudine (d4T) and of zidovudine (ZDV, AZT),
or switch to other drugs as prevention.
In naïve patients EFV has been associated with an increased
risk of lipoatrophy compared with ATV/r. In naïve patients
starting treatment with an ATV/r-containing regimen, an in-
creased visceral fat accumulation than with EFV was obser-
ved. In clinical trail on CCR5-antagonists or integrase inhi-
bitors an association with an increased risk of lipoatrophy
has not been observed.
Consider Nucleoside Reverse Transcriptase Inhibitors
(NRTI)-sparing regimens. Using these regimes may be asso-
ciated with an increase risk of dyslipidemia.
There are no antiretroviral therapy switch strategies with
proven efficacy in the treatment of lipo-hypertrophy.
In patients taking PI/r, the association with fluticasone (or
other inhalation corticosteroids) should be avoided due to
an increased risk of Cushing syndrome or of aseptic osteo-
necrosis.
→
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Prevention Management
Surgical intervention to correct facial lipo-atrophy is not ae-
sthetic surgery but repair of an iatrogenic injury. Indeed, the-
se have a positive effect on the quality of life and on depres-
sion, reducing the stigma of HIV disclosure and infection
“revealed” by recognition of the lipo-dystrophic phenome-
non, and is a potential intervention to support adherence to
antiretroviral therapy.
The surgical approach may be undertaken either by auto-
transplant of adipose tissue (lipo-filling) or by treatment with
synthetic fillers (re-absorbable or not), in patients without
adipose tissue for use as a donor site [BI]. The re-absorbable
synthetic fillers are preferable in patients with less severe li-
po-atrophy and under 50 years of age, while non re-absor-
bable synthetic fillers are preferred in cases of more severe
lipo-atrophy in those over 50 years old [BIII]. The use of
synthetic fillers is not recommended in the treatment of non
facial lipo-atrophy.
The use of medical therapies to improve lipo-atrophy has
produced conflicting results. In particular, the use of thiazo-
lidinediones such as rosiglitazone and pioglitazone did not
result in a significant increase of adipose tissue. Use of rosi-
glitazone can cause blood lipid elevations and an increased
risk of coronary heart disease.
Several drugs have been used to treat lipo-hypertrophy.
Growth hormone reduces visceral adipose tissue but may
exacerbate subcutaneous lipo-atrophy and insulin resistan-
ce. Tesamorelin (growth hormone release factor), currently
not authorized in Europe, has been shown to be efficacious
in reducing the volume of visceral adipose tissue. Metformin
reduces visceral adipose tissue in insulin resistant patients
but may exacerbate subcutaneous lipo-atrophy.
Surgical intervention to correct lipo-hypertrophy may be con-
sidered for removal of localised lipomas and to correct buf-
falo hump although the duration of the effect is variable
[BIII].
→
TABLE 27 - Prevention and management of patients at high risk of kidney disease
Prevention Management
Assessment of glomerular function is performed with pre-
diction algorithms which include serum creatinine level, age,
sex, ethnic origin and anthropometric measurements.
Calculation of creatinine clearance is necessary, as the se-
rum creatinine value depends to a variable extent on extra-
renal factors; further, the correlation between creatinine and
glomerular filtratation is not linear. Measurement urine over
24 hours, while more time-consuming, is more accurate and
certainly preferable to use of the Modification of Diet in
Renal Disease (MDRD), Cockcroft-Gault (CG), EPI-CKD for-
mulae.
Given the close connection between renal damage and car-
diac damage, cardiovascular prevention interventions, with
particular reference to hypertensive disease, appear effica-
cious in the prevention of kidney disease as well.
In cases of Fanconi syndrome in tenofovir-treated patients,
tenofovir must be discontinued immediately. In patients with
estimated glomerular filtrate <50 mL/min dose adjustments
should be performed where necessary.
The need for treatment modification should be assessed whe-
never GFR is below 60 ml/min and/or in the case of obser-
vation of proteinuria/ microhematuria.
In these cases, risk assessment for renal dysfunction is indi-
cated, discontinue or change drug doses where indicated,
and consider ultrasonography of the kidneys; in the case of
hematuria, irrespective of the degree of proteinuria, consult
a specialist nephrologist.
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FIGURE 1 - Clinical management of renal failure (1a) and proteinuria (1b).
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TABLE 28 - Prevention and management of patients at high risk of vitamin D deficit
Prevention Management
Factors associated with low level of vit D are represented by
coloured skin, low intake of vit D, lack of sun exposure, de-
fective intestinal absorption, obesity, cronic renal impaire-
ment, exposure to some antiretrovirals. Role of antiretrovi-
ral therapy in general or as specific drugs is not completely
defined. Vit D plasma levels represent an essential step in
the diagnosis of osteomalacia/osteoporosis and in patients
with cronic renal failure. When defect of Vit D is detected,
plasma levels of parathyroid hormone (PTH), calcium, pho-
sphorus, and alcaline phosphatase must be determined.
Replacement of vit D is recommended when plasma levels
of 25(OH)D is less than 30 ng/ml (75 nmol/l).
Hypophosforemia could be associated with TDF use. This
loss of phosphorus, caused by damage of proximal tubulus
could be independent from low levels of Vit D. Low levels of
calcium and phosphorus combined with low levels of alcali-
ne phosphatase could imply a defect of Vit D, whether or not
associated with osteomalacia.. Some experts suggest repla-
cement of Vit D in all HIV-infected patients, without need of
determining plasma levels. When deficit of Vit D is detected,
a load dose followed by a manteinace treamtn is advisable.
Although different regimens have been suggested, the load
dose could be performed with two consecutive doses of
300.000 UI per os and manteinance with a dose of 7000 UI
per os every 7 days. When a low intake of calcium with diet,
a replacement is advisable. 
Replacement of Vit D has been associated with a reduced in-
cidence of diabetes mellitus.
TABLE 29 - Treatment of sexual dysfunctions in men infected by HIV.
Treatment of erectile dysfunction Treatment of premature ejaculation
It is based on type 5 phosphodiesterase inhibitors (PDE5-Is),
such as sildenafil (Viagra®), tadalafil (Cialis®) and varde-
nafil (Levitra®) [113, 114]. The recommended initial dosages
for patients with HIV treated with protease inhibitors are: I
- Sildenafil 25 mg every 48 hours
- Tadalafil 5 mg as initial dose (do not exceed dosages above
10 mg in the 72-hour period) - Vardenafil 2.5 mg as maxi-
mal dosage in 72-hour period
Dosages of PDE5-Is higher than those generally recommen-
ded may be needed for patients receiving etravirine, a non nu-
cleoside reverse transcriptase inhibitor [115]. The three drugs
have to be taken in case of need half an hour before sexual
intercourse); for tadalafil, in patients with treatment response
in case of need and with presumably more frequent use of the
drug (i.e. at least twice a week), a daily administration sche-
me with lower drug dosages may be suitable [113]. Treatment
choice is based on personal preferences and on clinical ex-
perience.
Treatment of premature ejaculation is based on drugs as se-
lective serotonin reuptake inhibitors (SSRIs), tricyclic anti-
depressants, clomipramine, and topical anesthetics, though
behavioural treatment and psychosexual counseling may be
useful as well. It should be rememered that levels of clomi-
pramine and of other tricyclic antidepressants) may increa-
se with protease inhibitors and that these drugs should the-
refore be used at the lowest possible dosage [113, 114].
Dapoxetine, a potent SSRI with short action,is the only drug
with approval in Europe for the treatment of premature eja-
culation (to be taken in case of need) [113]. The frequency of
recommended dosage is once every 24 hours. Evaluation of
patient-reported benefits in respect to risks associated with
drug intake needs to be carried out after the first 4 weeks of
treatment (or after 6 doses) in order to define whether to
continue or stop treatment.
HIV-ASSOCIATED NEUROCOGNITIVE 
AND PSYCHIATRIC DISORDERS 
(Tables 30-33)
Neurocognitive disorders
The clinical outcome and quality of life of people
with HIV infection can be profoundly influenced
by the presence of neurocognitive and/or psychi-
atric disorders, whether these are the consequence
of HIV damage to the central nervous system
(CNS) - defined in this case as HIV-associated neu-
rocognitive disorders (HAND), attributable to oth-
er causes, or to the combination of the two.
HIV does not infect neurons directly, but the in-
fection and consequent activation of CNS
macrophages, the target cells in this tissue, can
trigger a cascade of events, including the pro-
duction of inflammatory, neurotoxic molecules
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TABLE 30 - Classification of HIV-associated neurocognitive disorders (HAND).
Alteration in ≥2 cognitive areas docu-
mented by NP exam
Interference with daily life
Asymptomatic Neurocognitive Impairment (ANI) Present No
Mild Neurocognitive Deficit (MND) Present Mild
HIV-associated dementia (HAD) Present Severe
HAND: HIV-Associated Neurocognitive Disorders; ANI: Asymptomatic Neurocognitive Impairment; MND: Mild Neurocognitive Disorder; HAD: HIV-Associated
Dementia; NP Exam: Neuropsychological Examination
While the incidence of HAD fell after the intro-
duction of combination antiretroviral therapy
(cART), the general prevalence of neurocognitive
disorders rose, likely due the increase over time
of incident cases and the longer survival of HIV-
infected individuals, and now affects 25%-50% of
patients. HAND is associated with several risk
factors, including:
- A CD4+ nadir <200 cells/µL;
- Age over 50 years;
- Cardiovascular risk factors, and/or disorders of
the lipidic or glucidic metabolism;
- Co-infection with HCV.
HIV-infected patients have a high prevalence of a
number of conditions/comorbidities that are in-
dependently associated with neurocognitive dis-
orders which may contribute to or totally explain
the cognitive deficit, and confound a diagnosis of
HAND:
- Depression;
- Anxiety disturbances;
- Psychoses and other psychiatric disorders;
- Vascular and ischemic dementia;
- Alzheimer’s disease;
- Opportunistic infections or CNS neoplasia;
- Metabolic encephalopathies;
- Hepatic cirrhosis;
- Co-infection with HCV;
- Current or previous history of drug abuse (co-
caine, methamphetamine, opiates);
- Abuse of psychiatric drugs;
- Alcoholism;
- Prior concussive cranial trauma.
A possible cause of neurologic or cognitive im-
pairment is the “CSF escape”, defined as a con-
dition of detectable HIV-RNA in CSF despite plas-
ma virological suppression, or of higher HIV RNA
levels in CSF than in plasma in patients on stable
treatment. CSF escape has been associated with
low CD4 nadir, long-term antiretroviral exposure,
history of multiple failure, and poor adherence
to treatment. 
This condition, which seems to reflect a com-
partimentalized infection, is not necessarily
symptomatic, and it has been observed in up to
10% of neuroasymptomatic patients. 
On the other hand, cognitive impairment is on-
ly unfrequently associated with CSF escape, and
it rather recognizes a multifactorial pathogen-
esis.
Diagnosis of HIV-associated neurocognitive dis-
orders (HAND)
The diagnostic procedures recommended for the
management of the patient with or at risk of
HAND are reported below.
leading to neuron dysfunction, degeneration and
death. The clinical equivalent of these events is
represented by a neurocognitive disorder which,
in more severe forms, manifests with a state of
dementia (HAD, HIV-associated dementia). A clas-
sification of HAND was recently proposed on the
basis of the severity of the deficit, as established
by neuropsychological examination. 
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FIGURE 2 -Diagnostic algorithm for the diagnosis and treatment of HIV-associated neurocognitive disorders (HAND).
Abbreviation legend - IHDS: International HIV Dementia Scale; MMSE: Mini Mental State Examination; IADL: Instrumental Activities
of Daily Living; NP Exam: Neuropsychological Examination; MRI: Magnetic Resonance Imaging of the brain with contrast media.
Notes on the algorithm: 1. Neurocognitive screening: tools; a) Test of the three questions; b. IDHS; c. MMSE. 2. Psychiatric sceening:
tools; a) Clinical history for previous psychiatric disorders or assumption of antipsycotic drugs; b. Patient Health Questionnaire
Depression Scale (PHQ9); c. Generalized Anxiety Disorder-7 (GAD-7). 3. Examinations for conditions/comorbidities associated with
non-HAND neurocognitive disorders: tools; a) Clinical history, clinical and neurological examination, blood tests, brain MRI, lumbar
puncture. The objective is to exclude potential causes of neurocognitive impairment (current or previous abuse of drugs, antipsy-
chotics or alcohol; cerebrovascula dementia; Alzheimer’s disease; CNS infections or neoplasms; metabolic encephalopathy; cirrhosis).
4. Neuropsychological tests; Instrumental Activity of Daily Living (IADL). 5. Brain MRI; lumbar puncture and CSF examination.
Examinations aims to identify HAND and exclude other pathologies. CSF analysis is primarily indicated to measure HIV-RNA level
(concomitant with evaluation of plasma viremia) and detect drug resistance. Lumbar puncture is recommended in patients with MND
or HAD [AII], and should be considered also in patients with ANI and risk factors for CSF viral escape (CD4 nadir <200 cell/mm3,
long-term duration of therapy, history of multiple failures or multi-drug resistance, poor adherence). (In case of CSF escape, the same
options for MND or HAND should be considered.). 6. Drugs recommended for high penetration and efficacy in the CNS. To define drugs
with high penetration and efficacy in the CNS, the use of Central nervous system Penetration Effectiveness - CPE Score (Letendre S et
al., CROI 2010) is recommended [see below], considering drugs with a CPE ranking score of 3 or 4. *In the case of negative results for
cognitive impairment or psychiatric disorders, a new evaluation after 6-12 months is recommended.
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TABLE 31 - Diagnostic route to diagnosis of HIV associated neurocognitive disorders (HAND)
Level Examination(s) Objective(s) Population
1 Screening test (3 questions,
IHDL)
Identification of patients with possible neuroco-
gnitive disorders
All [AIII]
2a Neuropsychological examina-
tion (NP)
Identification of patients with neurocognitive dis-
orders. Together with IADL and exams to exclu-
de other disorders: diagnosis of neurocognitive
impairment and definition of severity.
Patients with suggestive clinical
history or positive screening test
[AII];
2b IADL questionnaire Evaluation of functional impact.
Diagnosis of HAND severity
Patients with suggestive clinical
history or positive screening test,
or with altered NP exam [AII];
2c Other exams (laboratory and
instrumental tests, neurologi-
cal examination, psychiatric
evaluation*, brain MRI**, CSF
examination**)
Exclude confounding disorders. Together with
NP and IADL: diagnosis of HAND
Patients with suggestive clinical
history or positive screening
test, or with aletered NP exam
and functional involvement
[AII];
3 CSF analysis Exclude confounding disorders.
Assess HIV-RNA and GRT.
Patients with HAD or MND
[AII]; to be considered in ANI
with risk factors for “CSF esca-
pe” [BII].
GRT: Genotypic Resistance Test. *If altered psychiatric screening tests; **If MND or HAD
TABLE 32 - Antiretroviral therapy in patients with HAND
Clinical scenario and possible biological basis ARV therapy*
Off ARV
therapy 
Productive infection of CNS In patients with MND or HAD, ARV therapy with 3
drugs, all with high penetration and efficacy in the CNS,
also taking into account GRT in plasma and, if available,
in CSF [AII]. In patients with ANI, no data currently sug-
gest a treatment approach different from HIV general
population. In patients with ANI and CSF VL>plasma
VL, a regimen including drugs with elevated CSF pene-
tration/efficacy could be advisable [BIII].
On ARV
therapy,
virological
failure (plasma
VL >50
copies/mL)
a) HIV RNA in CSF >50 copies/mL: possible
productive infection of CNS;
b) HIV-RNA in CSF <50 copies/mL: possible
low-level HIV replication in CSF or CNS da-
mage due to other factors.
In patients with MND or HAD, modification of ARV the-
rapy on the basis of the GRT on plasma (a, b) and CSF
(a), using ARV drugs more effective or at least equiva-
lent to those included in current ART in terms of CNS pe-
netration and efficacy.
In patients with ANI, general criteria for management
of virological failure.
On ARV
therapy,
suppressed
viremia
(plasma VL
<50 copies/mL)
a) HIV-RNA in CSF >50 copies/mL: producti-
ve infection of CNS due to compartmentalised
viral replication (“CSF viral escape”). Possible
resistance in CSF and/or poor penetration/ef-
ficacy of ARV drugs in CNS;
b) HIV-RNA in CSF <50 copies/mL: possible
low-level HIV replication in CSF or CNS da-
mage due to other factors.
In patients with MND or HAD, modification of ARV the-
rapy on the basis of CSF GRT and previous resistance
tests on plasma, preferring agents with high CNS pene-
tration and efficacy (a) [AII].
Patients with ANI and CSF viral escape could benefit of
treatment including drugs with high CNS penetration
and efficacy [BIII].
*For drugs with elevated CNS penetration and efficacy, refer to CPE ranking score (see full version of the Guidelines), in which the drugs with higher pene-
tration and efficacy are assigned a higher score (3 or 4).
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Prevention of symptomatic HIV-associated
neurocognitive disorders (HAND) 
(MND, HAD)
In the absence of MND or HAD it is important to
identify the patients more at risk of developing
symptomatic neurocognitive impairment and to
employ effective strategies for its’ prevention. In
patients with ANI, monitoring of cognitive status
is indicated every 12 months, in order to detect
possible evolution toward symptomatic impair-
ment [AII]. 
In patients without neurocognitive alterations,
but with risk factors (CD4+ nadir <200 cells/µL,
age >50 years, metabolic disorders, co-infection
with HCV), neurocognitive monitoring by
screening test is indicated every 12 months to
evaluate possible evolution towards MND [AII].
In subjects without neurocognitive impairment
and no risk factors, a re-evaluation every 2-3
years is advisable [AII]. In patients with ANI and
risk factors of CSF escape (CD4 nadir <200
cell/mm3, long-term duration of therapy, history
of multiple failures or multi-drug resistance,
poor adherence), lumbar puncture with CSF ex-
amination should be considered [BII]. Cases with
CSF escape could benefit of a treatment based
on agents with high CNS penetration and effi-
cacy [BIII].
TABLE 33 - Monitoring the efficacy of antiretroviral therapy in HIV-Associated 
neurocognitive disorders (HAND).
Level Scenario Objective Examinations
1 Starting or changing cART,
HAND
Initial evaluation of the efficacy of
the (new) therapy on the
neurocognitive impairment
After 6 months: NP exam [AII] 
2° cART monitoring: HAND with
recovery of neurocognitive
impairment
Monitor the efficacy of cART on
the neurocognitive impairment
Every 12 months: NP exam [AII] 
2b cART monitoring: HAND with
no recovery or worsening of
neurocognitive impairment
Search for virological escape in
the CNS
Exclusion of other causes of
neurocognitive impairment
Neurological examination [AII]
MRI of the brain [AII]
CSF examination (HAD and MND) and
tests to exclude other disorders [AII], HIV
RNA [AII], GRT [AII]
After 6 months: NP exam [AII]
Psychiatric disorders
Psychiatric disorders may both cause cognitive
problems and confound HAND diagnosis. They
occur at a higher frequency in HIV-positive per-
sons than in the general population, and include
depression, anxiety, and other disturbances.
Depression and anxiety may be associated with
impaired memory and attention and mood
changes, and these pictures may either represent
a risk factor for, contribute to, or confound a di-
agnosis of HAND. 
Indeed, there is a relationship between depres-
sion and cortical degeneration or neuropsicho-
logical abnormalities [13-17]. In this context, it
is essential to recognize these disorders, to refer
the patient to the specialist for additional diag-
nostic work-up and, in case, to initiate a specific
treatment. To this aim, we suggest two simple
and quick tests (5-7 min) that can also be ad-
ministered by non-specialist personnel as a
screening approach to identify psychiatric prob-
lems: the Patient Health Questionnaire
Depression Scale (PHQ9) and the Generalized
Anxiety Disorder-7 (GAD-7) (attached).
Tumours
Treatment for HIV-associated tumours is very
complex and must be the product of a strategic
and operative agreement between the oncologist
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TABLE 34 - Antiretroviral therapy in HIV-infected individuals with coinfections with viral infections 
(HBV and HCV).
Coinfection with HCV Coinfection with HBV Cirrhosis
TDM - - Use in patients with
decompensated cirrhosis
When to start Recommended at a CD4 level <500 cell/mm3
What to start with 
(NRTI backbone)
Avoid didanosine and stavudine;
abacavir only after HLA-B*5701; avoid
abacavir in patients treated for HCV
with low-dose ribavirin or that have to
reduce ribavirin dosage due to side-
effects (anemia); avoid zidovudine if
the patient is candidate to Peg-
IFN+RBV
Use tenofovir+XTC; do
not use XTC as only
drugs active on HBV
-
What to start to
(third drug)
Avoid tipranavir and full-dose ritonavir; use nevirapine only as alternative
and the infectious disease specialist. This section
is intended to focus only on certain aspects of this
complex problem, mainly addressing the general
principles of timing, choice and management of
antiretroviral therapy in the HIV patient with ma-
lignancies. Thus, this discussion must not be con-
sidered an exhaustive review of the complex issue
of tumour management in the HIV-infected pa-
tient, a scenario which requires specific study and
recommendations in clinical, diagnostic and ther-
apeutic domains.
HIV-positive patients must regularly undergo
screening for solid cancers, in particular for
breast cancer, colorectal neoplasia and prostate
carcinoma, whose cost-efficacy is largely docu-
mented in the general population [AI].
Initiation of HAART is, in general, recommended
concomitant to the anti-neoplastic treatment
[AII], with the possible exception of patients with
non-AIDS defining cancers, elevated CD4+ levels,
and possible drug interactions associated with se-
vere with toxicity [BIII]. HAART is recommend-
ed in all patients treated with highly immuno-
suppressive therapies.
In candidate patients for concomitant treatment
with HAART and chemotherapy (CT), considera-
tion of possible drug-drug interactions and cu-
mulative toxicity must guide and orient the
choice of antiretroviral therapy.
The potential interactions between antiretrovi-
rals and chemotherapy should be considered be-
fore the a therapeutic regimen is chosen [AIII],
with reference to the most up to date data in the
literature (see http://www.hiv-druginteractions.
org). The use of antiretroviral TDM is recom-
mended to check for interactions and accumu-
lated toxicities [CIII].
INFECTIVE COMORBIDITIES 
(Tables 34, 35)
Infection by hepatitis viruses
When to start antiretroviral therapy 
Patients with hepatitis virus co-infection -
Maintenance of CD4+ count over 500 cells/L and
HIV viral suppression are recommended [BII].
Patients with HCV co-infection - With a CD4+
count >500 cells/µl, starting antiretroviral thera-
py is highly recommended [AII]. In patients with
indications for anti-HCV therapy with interferon
and ribavirin and with CD4+ <500 cells/L or
with unstable HIV disease (indicated by HIV-RNA
>100.000 copies/mL and/or decline of the CD4+
>100 cells/L in the last year) anti-HCV therapy
should be preceded by the initiation of antiretro-
viral therapy [AIII].
Patients with indication for anti-HBV therapy - In
patients with indications for treatment of chron-
ic hepatitis B, starting antiretroviral therapy is
recommended independently of the CD4+ count
and of the other parameters, administering teno-
fovir in combination with lamivudine or emtric-
itabine and a third drug or, alternatively, teno-
fovir with another nucleoside active on HBV (tel-
bivudine or entecavir) in addition to another two
antiretrovirals [AII].
→
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Coinfection with HCV Coinfection with HBV Cirrhosis
Use NNRTI or PI or Integrase inhibitor
with a low impact on insulin
resistance.
No other indications Saquinavir not indicated in
decompensated cirrhosis;
adjust dosing in Child-Pugh
classification of Class B*; use
TDM if Child-Pugh
classification of Class C 
Management of first
failure and
successive or
alternative
treatment strategies
- Do not discontinue
anti-HBV drugs if
staging is >F2
according with
METAVIR
-
*Caution and monitoring of side-effects in the case of hepatic impairment (Child-Pugh ≥7 points) when efavirenz, lopinavir/r, raltegravir, maraviroc are used;
in patients with severe hepatic impairment increasing levels of plasma concentration of efavirenz and maraviroc have been observed [BIII]. Use atazanavir
at dosing of 300 mg daily (without ritonavir) in patients with cirrhosis and Child-Pugh score between 7 and 9 [BII]. In adults with mild hepatic impairment
(Child-Pugh score 5-6 points) the recommended dosing of fosamprenavir is 700 mg BID with ritonavir 100 mg daily [BII]. In adults with moderate hepatic
impairment (Child-Pugh score 7-9 points) the recommended dosing of fosamprenavir is 450 mg BID with ritonavir 100 mg daily.
In patients receiving telaprevir, do not use lopinavir/r, darunavir/r or fosamprenavir/r. Possible using atazanavir/r or efavirenz (increasing daily dosage of te-
laprevir up to 1125 mg TID). Use of telaprevir increases exposure to tenofovir. In patients treated by boceprevir, boosted protease inhibitors should be avoi-
ded. In general, use cautiously anti-HCV direct-acting antivirals (DAA) in antiretroviral setting, due to limited information and high-level drug-drug interac-
tions with antiretroviral drugs.
→
Liver toxicity in HIV coinfected with hepatitis viruses
Acute viral or drug-related hepatitis SpeciÞc protocols
Stop treatment
No
No
Yes
Yes
Yes
No
Continue cART with intensive follow-up with at least monthly controls of hepatic
parameters and investigate causes of LEE including liver biopsy
Consider HBV reaction and
maintain HBV therapyHBsAg+ and HBV-DNA+
Lactic acidosis
Hypersensitivity reaction (HSR)
Liver enzyme elevation (LEE) >10-fold upper
normal limits and at least 5-fold basal values
Jaundice or signs of liver failure
FIGURE 3 -Management of liver toxicity in HIV-infected individuals treated with antiretrovirals.
Tuberculosis
The critical passages regarding the use of com-
bination antiretroviral therapy (cART) in subjects
with tuberculosis are:
Optimal timing of cART initiation with respect
to the tuberculosis treatment.
The selection of antiretroviral drugs to be ad-
ministered with the tuberculosis therapy on the
basis of assessment of potential pharmacoki-
netic interactions and possible cumulative tox-
icity.
The risk of developing an immune reconstitution
(inflammatory) syndrome (IRIS) after initiation
of cART and its management.
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TABLE 35 - Principles of ARV management in HIV-infected patients with tuberculosis
Recommendations Comments
When to start Strongly recommended to start cART during
anti-tubercular therapy, independently from
CD4 count or plasma HIV-RNA levels [AI].
In patients with CD4 <50 cells/mm3 initiation of
ART is recommended at 2 weeks from starting of
anti-tubercular therapy [AI];
In patients with CD4 50-500 cells/mm3 initiation
of ART is recommended from 2 weeks to 2 months
from starting of anti-tubercular therapy [AI];
In patients with CD5 >500 cells/mm3: initiation to
be established on individual basis, according with
cost-benefit evaluation
When to start Strongly recommended to start cART during
anti-tubercular therapy, independently from
CD4 count or plasma HIV-RNA levels [AI].
In patients with CD4 <50 cells/mm3 initiation of
ART is recommended at 2 weeks from starting of
anti-tubercular therapy [AI];
In patients with CD4 50-500 cells/mm3 initiation
of ART is recommended from 2 weeks to 2 months
from starting of anti-tubercular therapy [AI];
In patients with CD5 >500 cells/mm3: initiation to
be established on individual basis, according with
cost-benefit evaluation
What to start with EFV+2NRTI is the choice regimen to be
combined with a rifampin-based tuberculosis
regimen [BI].
Use of PI/r or PI (except for unboosted
saquinavir) is feasible if combined with
rifabutine [BII]. All these combinations
should be used in patients with NNRTIs
resistance or tolerance.
The use of PI/r or PI combined with rifampin is
contraindicated. 
Immune
reconstitution
syndrome (IRIS)
after cART
initiation 
Delaying cART initiation after the first
months from starting tuberculosis treatment,
the incidence and severity of IRIS could be
reduced. This strategy is not recommended in
patients with CD4 <350 cell/mm3 [AI]. Do not
discontinue cART in case of IRIS [AII]
OPPORTUNISTIC INFECTIONS 
(Tables 36, 37)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 143
TABLES 36 - Initiation of antiretroviral therapy during acute opportunistic infection.
ElementS WHIch MUST BE considerED includE THE DEGREE OF immuno-sUppression, THe availability OF effective
THERAPY FOR O.I.s, pharmacological INTERACTIONS AND cumulative toXicitY, AND THE RISK OF IRIS
In the absence of obvious contraindications, early initiation of ART in the initial phases of an acute O.I.
Immediate initiation of ART is highly recommended in patients with opportunistic infections for which efficacious speci-
fic therapies are lacking, such as cryptosporidiosis, microsporidiosis, progressive multifocal leukoencephalopathy (PML),
localized cutaneous and mucosal Kaposi sarcoma (KS), multi-resistant herpes simplex infection [AII].
In patients with PCP initiation of ART is highly recommended within 2 weeks of the diagnosis of PCP [AI].
In O.I.s in which the risk of IRIS is higher (tuberculosis, cryptococcal meningitis, atypical micobacterial infections, CMV
infection), delayed initiation of ART may be considered.
TABLE 37 - Management of opportunistic infections during antiretroviral therapy.
Opportunistic infections Considerations
<12 weeks of ART - Administer anti-O.I. therapy
- Continue ART [AIII]
- Consider IRIS
>12 weeks of ART with virological suppression and
immunological recovery
- Administer anti-O.I. therapy
- Continue ART [AIII]
- Consider IRIS
Assess whether to modify or intensify ART in case of
suboptimal recovery of CD4+ lymphocytes [CIII]
>12 weeks of ART with virological failure - Perform resistance test [AI]
- Administer anti-O.I. therapy
- Modify ART [AI]
ANTIRETROVIRAL THERAPY 
IN PREGNANCY 
(Table 38)
General aspects of antiretroviral treatment
during pregnancy
Many aspects of antiretroviral therapy in preg-
nancy are as yet unclear due to the difficulty of
conducting randomized clinical studies in this
setting and the difficulty of responding to partic-
ular clinical questions through controlled clini-
cal or observational studies. 
In particular, there is no evidence to guide: the
optimal timing antiretroviral treatment initia-
tion in pregnancy for women who have no oth-
er indication for the treatment, which choice of
drugs and regimens is safe to continue during
the pregnancy, and what is the long-term impact
of antiretroviral therapy during pregnancy on
survival.
Approach to antiretroviral therapy in preg-
nancy
The recommended therapeutic approach is based
on the combined administration of ante partum
and intra partum maternal therapy and on an-
tiretroviral prophylaxis in the newborn [AI]. This
therapeutic schema should be applied to all preg-
nant women with HIV, independent of the CD4
and HIV-RNA values [AI]. Where, due to late ac-
cess to treatment, the ante partum or intra par-
tum therapy cannot be delivered, administration
of the remaining components of the therapeutic
schema is fundamental [AII].
It is necessary to consider separately women with
maternal indications for antiretroviral therapy
and those whose sole indication is the prevention
of vertical transmission.
Principal therapeutic scenarios
Pregnant women with maternal indication for
antiretroviral treatment must receive a combi-
nation regimen of potency analogous to that rec-
ommended in non-pregnant women [AI]. If the
woman is not yet undergoing treatment and
there is indication for immediate treatment, it
must be initiated as soon as possible [AII].
For women with no indication for antiretroviral
therapy, the general recommendation is to ad-
minister, in all cases, a potent combination reg-
imen, as combination regimens have been found
to be the most effective in preventing vertical
transmission [AII].
Independent of the individual indication for an-
tiretroviral therapy in pregnancy (presence or oth-
erwise of the maternal indication for treatment
in addition to prevention of vertical transmis-
sion), the use of antiretroviral mono-therapy in
pregnancy should be considered inadequate due
to its suboptimal antiviral efficacy, the higher risk
of development of resistance, and the greater ef-
ficacy of the combined therapy in preventing ver-
tical transmission.
Pregnancy is characterized by significant physi-
ological changes operating at different levels on
absorption, distribution, metabolism and elimi-
nation of drugs. Reduced plasma levels of drugs
in pregnancy have been reported by diverse au-
thors, especially in the third trimester, most fre-
quently protease inhibitors, which show greater
variability than NRTI and NNRTI.
Monitoring plasmatic drug levels
In general, plasmatic drug level monitoring is not
recommended (TDM) in all pregnant women with
HIV undergoing treatment, but should be con-
sidered in particular situations (e.g.: pathologies
or concomitant treatments which can signifi-
cantly interfere with the metabolism, drugs or reg-
imens particularly those for which there is no
available data during pregnancy, toxicity or inef-
ficacy of unclear cause, need to precisely define
the levels relative to the presence of resistance,
etc.). For the management of these problems, in-
creasingly interesting and growing in complexity,
please refer to the specific section dedicated to
Pharmacological Monitoring and Interactions.
Virological monitoring during pregnancy: vi-
ral load and resistance
Virological objectives of antiretroviral treat-
ment in pregnancy
Viral load monitoring in pregnancy is of partic-
ular relevance as the maternal viral load is an
independent determinant of vertical transmis-
sion. It is thus particularly important to main-
tain the viral load undetectable in women at the
beginning of the pregnancy and to achieve viral
suppression of HIV as rapidly as possible to un-
detectable levels in women commencing treat-
ment during pregnancy [AII].
Viral load monitoring may be performed every
two-three months in women on stable therapy
and with undetectable HIV at baseline, while in
women commencing treatment or requiring mod-
ification during pregnancy closer monitoring of
response to treatment is advised. An HIV-RNA
assessment is recommended in all women at
about week 34-36 of gestation.
Therapeutic failure
In the presence of therapeutic or virological fail-
ure, it is necessary to rapidly modify the treat-
ment in order to guarantee the lowest possible
levels of viral load at the time of delivery. To his
end, a resistance test to guide the choice of treat-
ment is highly recommended [AI].
Performance of resistance testing
The use of the resistance assay during pregnan-
cy, follows the general directives regarding adults
a resistance test is recommended in all women
not yet on treatment [AIII] and in all those un-
dergoing treatment with a confirmed detectable
RNA [AI]. 
The test must be ordered in a timely manner, and
optimal period for delineation of resistances and
choice the treatment in pregnancy is the pre-con-
ception period.
Antiretroviral therapy in women already un-
dergoing treatment at conception
Ideally, the regimen at conception should have
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been selected in the pre-conception period ac-
cording to criteria which assure safe usage in
pregnancy, so that modification or interruption
is not required in the early weeks of gestation. In
prescribing potentially teratogen drugs (e.g.
efavirenz) to women of reproductive age or oth-
er regimens or drugs characterised by addition-
al risk of toxicity in pregnancy (e.g. lactic aci-
dosis, hepatotoxicity, diabetes), it is necessary
to consider the possibility of an unplanned preg-
nancy and individually assess the risk/benefit of
treatment relative to the risk of unplanned preg-
nancy. 
In women undergoing antiretroviral treatment
with unplanned pregnancy, the regimen must be
re-assessed as soon as possible in order to de-
termine its safety for use in pregnancy [AII].
Antiretroviral treatment in women who have
never received antiretrovirals prior to preg-
nancy
Choice of the treatment regimen
Where there is a maternal indication for treat-
ment, it must commence as soon as possible, al-
so in the first trimester, using a potent regime of
a combination of drugs which has the best evi-
dence for safety in pregnancy.
Where the indication for treatment is solely for
prophylaxis of vertical transmission, it is possi-
ble to consider and discuss with the patient ini-
tiation of treatment after the first trimester, but it
is necessary to consider that in the absence of
treatment there is a risk of ante partum trans-
mission.
Timing of starting treatment
It is not possible to recommend, on the basis of
the available evidence, an optimal timing for
starting of the antiretroviral treatment in preg-
nancy for women with no personal indication
for treatment [9], but the trimester for initiation
of the treatment must guarantee a therapy du-
ration sufficient to achieve complete viral sup-
pression in the final phases of the pregnancy, al-
so considering the possibility that the duration
of the pregnancy may be reduced by the risk of
pre-term birth.
Potency of the regimen
In all women, including those with no person-
al indication for treatment, the potency of the
regime must be adequate to achieve complete
viral suppression, and in general, combination
regimens must used at the same potency of
those recommended for the treatment of all
adults [AI]. 
In the case of women with viral loads below
1000 copies/mL in the absence of treatment, con-
troversy remains as to whether regimens of less-
er potency than those used for treatment of
adults are to be recommended.
Interruption of treatment
In the case of interruption of antiretroviral treat-
ment during pregnancy, treatment interruption
must be immediate and simultaneous for all
drugs in cases of severe and life threatening tox-
icity or grave hyperemesis [AIII]. In case of elec-
tive interruption, in order to prevent the selection
of resistant strains, if agents with a long half-life
are part of the regimen (e.g. NNRTI, non nucle-
oside analogues), it is strongly recommended the
sequential discontinuation of drugs with long
half lives first, with continued administration of
other regimen components for a period of time
sufficient to guarantee triple antiretroviral cov-
erage as NNRTI levels diminish [AII]. 
Continued administration of the other drugs for
at least 7 days may be considered sufficient, but
there is notable variability in the time at which
the NNRTIs become undetectable in plasma after
discontinuation. Recent Italian data, while limit-
ed to a number of vertical transmission cases and
not exclusively involving HAART therapies but
including monotherapy (10.6%) and dual thera-
py (20.0%), suggest that interruptions of treat-
ment in pregnancy may constitute a significant
risk factor for mother-to-child HIV transmission.
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TABLE 38 - Considerations on cost-benefit ratio and on safety of single drugs during pregnancy.
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Zidovudine First choice as NRTI during pregnancy. It has been the first drug with a proven efficacy in prevention of
mother to child transmission (MTCT) of HIV. Its inclusion in a regimen starting during pregnancy is ad-
visable for its ability to cross the placenta. ZDV represents the drug with the most numerous reports on
safety during pregnancy. If ZDV is included in the regimen at conception, in absence of toxicity or resi-
stance, the continuation of the drug is advisable.
Lamivudine First choice as NRTI during pregnancy. As for ZDV, a large experience on its use during pregnancy is avai-
lable, in terms of tollerability and safety. It’s active on HBV. Possible reactivation of HBV disease after
stopping lamivudine.
Emtricitabine Alternative choice to lamivudine, but less information available.
Tenofovir Data available on safety of tenofovir during pregnancy are growing, but still limited. Risks of foetal ab-
normalities does not seem superior compared to that of other antiretrovirals. Toxicity characteristics co-
uld suggest potential risk of abnormal bone development in the foetus and nefrotoxicity in the mother.
Preliminary studies with limited power did not demonstrated such effects.
When tenofovir is included in the regimen, the monitoring of renal function is recommended. 
Due to its activity on HBV, the cost/ benefit ratio of using it during pregnancy may be favourable in HBV
coinfected women who need treatment for HIV or HBV, if associated with nucleosides with anti HBV ac-
tivity (lamivudine or emtricitabine). Reactivation of HBV disease is possible if the drug is stopped. 
Didanosine It is not considered a first choice- NRTI, but its use is acceptable. Data from Antiretroviral Pregnancy
Registry (APR, which represent the widest case series on antiretroviral and congenital defects), demon-
strated a slight increase of congenital defects in newborns exposed to DDI during the first three months
of pregnancy, without any particular pattern of defects. Based on the current proportion of congenital de-
fects in DDI-exposed newborns observed in APR (4.6%), as well as on lack of evidence of a particular pat-
tern, this slight increase has not been considered as actually causative of increased risk of congenital de-
fects. The association with stavudine has to be avoided in presence of alternative chances. 
Abacavir Potential risk of hypersensitivity reaction in patients with genetic predisposition (HLA-B*5701). Three
nucleosides-based regimens containing abacavir showed less efficacy compared with NNRTI- or PI/r-
based regimens and should be avoided in the presence of more efficacious alternative chances. 
Stavudine The association with DDI should be avoided in presence of alternative chances. Stavudine should not be
associated with zidovudine for pharmacologic antagonism. 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz Use of efavirenz has been associated with a risk of abnormalities during embriogenesis. When prescribing
Efavirenz to a child-bearing women it is recommended to inform the women on its potential risks. Its use
should be avoided in women planning a pregnancy or without adequate contraception [AIII]. 
Similarly, the start of efavirenz must be avoided during the first tremester of pregnancy [AIII]. Recent da-
ta from meta-analysis as well as from Antiretroviral Pregnancy Registry, do not find that exposure to efa-
virenz during the first trimester is not associated with a significantly higher risk of congenital defects
than that observed with other antiretrovirals. In women who become pregnant during an efavirenz-based
regimen, considerations on interrruption of pregnancy or change of therapy must take into account the
period of pregnancy as well as the long half-life of the drug, considering that the closing of neural tube
occurs during the sixth week of pregnancy.
Nevirapine The risk-benefit ratio of starting a nevirapine-based regimen during pregnancy is still controversial. Women
starting nevirapine at CD4+>250 cells/mmc, an increased risk of epatotoxicity has been described, apart
from concomitant rash, even lifetreathning. 
This increased risk of liver toxicity has not been confirmed in all studies of pregnant women and data from
multicenter cohort studies did not find an increased risk in women on nevirapine-based regimens com-
pared to other aniretrovirals. 
Nevertheless, HIV-pregnant women have an increased risk of epatotoxicity compared with non-HIV pre-
gnant women. Al these considerations must be taken into account in the cost-benefit evaluation of using
nevirapine during pregnancy. 
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Etravirine Data on its use during pregnancy are not yet available. 
Protease inhibitors (PI)
Lopinavir/r First choice among PI for use during pregnancy. Lopinavir represents the PI for which more infor-
mation is available on its use during pregnancy. Data assessed a favourable balance between potency
and safety in pregnancy. 
Atazanavir Exposure to atazanavir during pregnancy is increasing. Data are sill limited and risk of abnormali-
ties sems to be not higher to those of other antiretrovirals. Theoretical probability of worsening of
physiological hyperbilirubinemia of newborn. 
Potential reduced plasma levels if used without ritonavir or if associated with tenofovir.
Saquinavir Limited data during pregnancy. To be boosted with ritonavir. 
Fosamprenavir Sufficient information on its use in pregnancy is not available. 
Tipranavir Sufficient information on its use in pregnancy is not available.
Darunavir Sufficient information on its use in pregnancy is not available.
Nelfinavir Drug of the most frequent use up to 2007, with a favourable safety profile. 
Between 2007 and 2008 it has been temporarely withdraw from commerce in Europe, for the pre-
sence of etilmetansulfonate (EMS), a potentiallly teratogen, mutagen and carcinogen compound. For
its use during pregnancy, it must be considered that in clinical trials apart from pregnancy it de-
monstrated lower rates of virological response compared to LPV/r. 
Indinavir To use in the absence of other therapeutic chances, if associated with ritonavir. Theoretical proba-
bility of worsening of physiological hyperbilirubinemia of newborn. 
HIV inhibitors of other drug classes
Raltegravir Although sufficient data for recommending its use during pregnancy do not exist, the drug could
be potentially useful in highly viremic setting in the last period of pregnancy, when reducing the
plasma viremia before delivery is mandatory. 
Maraviroc Sufficient information on its use in pregnancy is not available.
Enfuvirtide Limited information on its use during pregnancy is available. The drug seems to not be able to cross
the placenta, and it has been used unfrequently in the last period of pregnancy to riduce plasma vi-
remia, particularly in presence of a multiresistant virus.
→
POST-EXPOSURE PROPHYLAXIS 
(Tables 39, 40)
Indications for post-exposure prophylaxis
- PEP must be initiated as soon as possible after
exposure, preferably within 1-4 hours, and no
later than 48 hours [AII].
- Exposed subjects who have initiated PEP must
be evaluated by an expert within 48-72 hours
of treatment initiation [AIII].
- In those cases where the serostatus of the
source patient is unknown and the source pa-
tient is available, a targeted epidemiological in-
vestigation should be conduced and a serolog-
ical test performed, once consent has been ob-
tained; the result must be rapidly available, and
where available rapid tests could be used [AIII].
- Where serological testing is not possible in the
time available, commencement of treatment is
recommended with a new visit planned to re-
evaluate transmission risk, once source-patient
test results have been obtained [AIII].
- An exposure source patient who refuses con-
sent to testing must be considered HIV-infect-
ed [AIII].
- Tests based on detection of antigens and anti-
bodies are preferable. Use of bio-molecular
techniques is not indicated for the purpose of
ascertainment of infection [AII].
- Performance of ad hoc tests to determine re-
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TABLE 39 - Recommendations for offering PEP
a) OCCUPATIONAL EXPOSURE
Exposure Mode Source Patient
Needle used in vein or artery
Deep lesion with needle or solid cutting device visibly con-
taminated with blood.
HIV+*
or
HIV negative but with history or current pathology indicati-
ve of very recent at risk exposure (e.g. acute viral hepatitis,
STI, endocarditis of right heart)
or
Refusing to consent to serology test for HIV
Conjunctival contamination with blood or CSF
Exposure to material with elevated viral concentration (e.g.
cultures, concentrated suspensions of virus) in any moda-
lity.
HIV+*
* The risk is significantly reduced if the source is on ARV therapy with consistently undetectable viral load in recent months.
In situations other than those indicated, PEP may be considered by an expert on the basis of careful assessment of the risk taking into account the efficiency
of transmission connected with the exposure modality and the contagiousness of the source.
b) NON OCCUPATIONAL EXPOSURE
Exposure Mode Source Patient
Receptive anal, vaginal, oral sex with internal ejaculation HIV+*
or
HIV negative but with history or current pathology indicati-
ve of very recent at risk exposure (e.g. acute viral hepatitis,
STI, endocarditis of right heart)
or
Serology for HIV not known in subject with high risk beha-
viour 
or
in the case of rape/sexual violence 
Insertive anal or vaginal sex
Without protection or inefficacious protection ^
HIV+*
Receptive anal, vaginal, oral sex
No internal ejaculation
no protection
HIV+*
or
in the case of rape/sexual violence
Exchange of syringe or other material in common use for
intravenous drug abuse 
Independent of the serological state of the source
*The risk is significantly reduced if the source is on ARV therapy with consistently undetectable viral loads in recent months;; risk is augmented if trauma is
verified (e.g. traumatic injury after rape), if there is a presence of blood or current STI especially if with ulcerating disease. ^the risk is lower if  circumcised.
In situations other than those indicated, PEP may be considered by an expert on the basis of careful assessment of the risk taking into account the efficiency
of transmission connected with the exposure modality and the contagiousness of the source.
sistance to the ARVs is not recommended [AIII].
- During initial counseling of the exposed sub-
ject, the risks connected with the specific ex-
posure must be explained in order to facilitate
correct perception of the probability of infec-
tion and facilitate decision-making on PEP up-
take [AIII].
- Individuals taking PEP should receive an en-
hanced risk reduction and adherence counsel-
ing, and an active follow-up [AII].
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Prophylaxis regimes
PEP must be composed of a three drug combi-
nation regime [AIII].
PEP must be continued for 28 days [AIII].
In the case of an HIV positive source, the choice
of drugs must be guided by the resistance profile
by genotyping, if available, or from the chart re-
view [AII].
The medical history of the exposed and eventual
interactions with other drugs must be considered
in the choice of the drugs [AIII].
In case of post-coital contrapception, PEP regi-
mens including efavirenz or protease inhibitors
boosted with ritonavir should be avoided. [AII].
Any combination of ARV drugs approved for the
treatment of patients with HIV infection may be
used for PEP, with the same contraindications,
including new drugs which become available in
the future [AIII].
At this time nevirapine is the sole drug whose use
is not recommended, in the presence of alterna-
tives, due to severe toxicity in immune compe-
tent subjects. The use of stavudine and of aba-
cavir should be reserved solely for those cases
without valid alternatives, due to possible serious
reactions [AII].
Pregnancy is not an absolute criterion for exclu-
sion from PEP; for pregnant women is not rec-
ommended the use of efavirenz (possible terato-
genicity), stavudine and didanosine (lactic aci-
dosis), indinavir (hyperbilirubinaemia as birth
approaches) [AII].
TABLE 40 - Antiretroviral regimens recommended and alternative for PEP.
Regimes
Recommended regimen 2 N(t)RTI + PI/r 
Alternative regimen* 2 N(t)RTI + INI (Integrase Inhibitor) 
*especially in cases of post coital contraception
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